Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors

Cancer Immunology Immunotherapy

Volumn 49, Issue 4-5, 2000, Pages 259-266

  Bergman, Ira ^a,b   Basse, Per H ^a   Barmada, Mamdouha A ^a   Griffin, Judith A ^b   Cheung, Nai Kong V ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antibody dependent cytotoxicity; Complement; Eosinophils; Neutrophils

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL DESTRUCTION; CANCER IMMUNOLOGY; CELL MEDIATED CYTOTOXICITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; EOSINOPHIL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033941038     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620000120     Document Type: Article

References (29)

1. Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH (1991) Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 174: 479
2. Bergman I, Arbit E, Rosenblum M, Larson SM, Heller G, Cheung NK (1993) Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8. J Neuro-Oncol 15: 235
3. Bergman I, Barmada MA, Heller G, Griffin JA, Cheung NK (1999) Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8. Int J Cancer 82: 538
4. Chen S, Caragine T, Cheung NKV, Tomlinson S (2000) Surface antigen expression and complement succeptibility of differentiated neuroblastoma clone. Am J Pathol (in press)
5. Cheung NK, Yu A (1999) Immunotherapy of neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA (eds) Neuroblastoma. Elsevier Science, Amsterdam
6. Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF (1985) Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45: 2642
7. Cheung NK, Pentlow K, Graham MC, Yeh SDJ, Finn RD, Larson SM (1992) Radiation absorbed dose and tumor response during therapy with iodine-131 conjugated 3F8 monoclonal antibody. In: Fifth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge Associated Universities, Oak Ridge, Tenn
8. Davis TA, Czerwinski DK, Levy R (1999) Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 5: 611
9. Farah RA, Clinchy B, Herrera L, Vitetta ES (1998) The development of monoclonal antibodies for the therapy of cancer. Crit Rev Eukaryotic Gene Expression 8: 321
10. Fine DP, Marney SR Jr, Colley DG, Sergent JS, Des Prez RM (1972) C3 shunt activation in human serum chelated with EGTA. J Immunol 109: 807
11. Gavin AL, Barnes N, Dijstelbloem HM, Hogarth PM (1998) Identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity. J Immunol 160: 20
12. Gessner JE, Heiken H, Tamm A, Schmidt RE (1998) The IgG Fc receptor family. Ann Hematol 76: 231
13. Greenwood J, Clark M, Waldmann H (1993) Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 23: 1098
14. Ide M, Weiler D, Kita H, Gleich GJ (1994) Ammonium chloride exposure inhibits cytokine-mediated eosinophil survival. J Immunol Methods 168: 187
15. Junghans RP (1990) A strategy for evaluating lymphokine activation and novel monoclonal antibodies in antibody-dependent cell-mediated cytotoxicity and effector cell retargeting assays. Cancer Immunol Immunother 31: 207
16. Jurcic JG, Scheinberg DA, Houghton AN (1997) Monoclonal antibody therapy of cancer. Cancer Chemother Biol Response Modif 17: 195
17. Kierszenbaum F, Ackerman SJ, Gleich GJ (1982) Inhibition of antibody-dependent eosinophil-mediated cytotoxicity by heparin. J Immunol 128: 515
18. Kushner BH, Cheung NK (1989) GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73: 1936
19. Lehrer RI, Lichtenstein AK, Ganz T (1993) Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol 11: 105
20. Lopez AF, Nicola NA, Burgess AW, Metcalf D, Battye FL, Sewell WA, Vadas M (1983) Activation of granulocyte cytotoxic function by purified mouse colony-stimulating factors. J Immunol 131: 2983
21. Lopez AF, Strath M, Sanderson CJ (1983) Mouse immunoglobulin isotypes mediating cytotoxicity of target cells by eosinophils and neutrophils. Immunology 48: 503
22. Munn DH, Cheung NK (1987) Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 47: 6600
23. Ong GL, Mattes MJ (1989) Mouse strains with typical mammalian levels of complement activity. J Immunol Methods 125: 147
24. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659
25. Ribeiro U Jr, Basse PH, Rosenstein M, Safatle-Ribeiro AV, Alhallak S, Goldfarb RH, Posner MC (1997) Retention of adoptively transferred interleukin-2-activated natural killer cells in tumor tissue. Anticancer Res 17: 1115
26. Ribeiro U Jr, Whiteside TL, Basse PH, Safatle-Ribeiro AV, Huneke CE, Posner MC (1999) Activated natural killer cell tumor retention and cytokine production in colon tumor using a tissue-isolated model. J Surg Res 82: 78
27. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343: 1177
28. Schlom J (1995) Monoclonal antibodies in cancer therapy. In: Devita VT, Hellman S, Rodenberg SA (eds) Biological therapy of cancer: principles and practice. Lippincott, Philadelphia, p 507
29. Ward RL, Hawkins NJ, Smith GM (1997) Unconjugated antibodies for cancer therapy: lessons from the clinic. Cancer Treat Rev 23: 305